Treatment of elderly patients with glioblastoma: new lessons from CE.6

The introduction of radiation therapy (RT) with concurrent temozolomide (TMZ) by the EORTC-NCIC trial (the Stupp trial) resulted in a significant evolution in the treatment of adult patients with glioblastoma. The Stupp trial confirmed a significant improvement in overall survival with the addition of concurrent and adjuvant TMZ to radiotherapy (1). Further, for the first time, patients with glioblastoma began to achieve longer-term survival, with nearly 40% alive at 2 years, and nearly 10% alive at 5 years (2).